Overview

Variant Type
Low Expression

Significance of PD-L1 Low Expression (TPS = 1-49.999%) in Diseases

Non-Small Cell Lung Carcinoma +

Squamous Cell Lung Carcinoma +

Lung Adenocarcinoma +

Malignant Solid Tumor +

Non-Squamous Non-Small Cell Lung Carcinoma +

Ampulla Of Vater Carcinoma +

Bladder Urothelial Carcinoma +

Cholangiocarcinoma +

Distal Bile Duct Carcinoma +

Gallbladder Carcinoma +

Infiltrating Renal Pelvis And Ureter Urothelial Carcinoma +

Intrahepatic Cholangiocarcinoma +

Large Cell Lung Carcinoma +

Renal Pelvis Urothelial Carcinoma +

Ureter Urothelial Carcinoma +

Urethral Urothelial Carcinoma +

Urothelial Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.